TCR² Therapeutics to Participate in Two Upcoming Conferences in June
May 26 2021 - 6:45AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from cancer, today announced that management
will participate at two upcoming conferences in June using a
virtual platform.
- Ian Somaiya,
Chief Financial Officer of TCR2 Therapeutics, will present an
update on Company progress at the Jefferies Virtual Healthcare
Conference on June 2, 2021 at 2:30pm ET
- Management will participate in a
fireside chat at the Goldman Sachs 42nd Annual Global Healthcare
Conference on June 9, 2021 at 9:40am ET
A live webcast of each presentation will be
available on the Investors page of the Company’s website at
www.investors.tcr2.com. An archived replay will be available for at
least 30 days following the presentation.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from solid tumors or
hematological malignancies. TCR2’s proprietary T cell
receptor (TCR) Fusion Construct T cells (TRuC®-T cells)
specifically recognize and kill cancer cells by harnessing
signaling from the entire TCR, independent of human leukocyte
antigens (HLA). In preclinical studies, TRuC-T cells have
demonstrated superior anti-tumor activity compared to chimeric
antigen receptor T cells (CAR-T cells), while secreting lower
levels of cytokine release. The Company’s lead TRuC-T cell product
candidate targeting solid tumors, gavo-cel, is currently being
studied in a Phase 1/2 clinical trial to treat patients with
mesothelin-positive non-small cell lung cancer (NSCLC), ovarian
cancer, malignant pleural/peritoneal mesothelioma, and
cholangiocarcinoma. The Company’s lead TRuC-T cell product
candidate targeting hematological malignancies, TC-110, is
currently being studied in a Phase 1/2 clinical trial to treat
patients with CD19-positive adult acute lymphoblastic leukemia
(aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
For more information about TCR2, please
visit www.tcr2.com.
Investor and Media Contact:
Carl MauchDirector, Investor Relations and
Corporate CommunicationsTCR2 Therapeutics Inc.(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Sep 2024 to Oct 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Oct 2023 to Oct 2024